Results 191 to 200 of about 71,509 (231)

Recent Advances in Interventions Targeting Remyelination and a Systematic Review of Remyelinating Effects of Approved Disease‐Modifying Treatments for Multiple Sclerosis

European Journal of Neurology, Volume 32, Issue 11, November 2025.
ABSTRACT Background Regenerative strategies in progressive multiple sclerosis (MS) pose a significant unmet need. Combining immunomodulatory treatment with remyelinating interventions to target the complex underlying pathogenesis appeals as the next frontier in MS therapeutic developments.
Anna‐Victoria De Keersmaecker, Eline van Doninck, Inez Wens, Yousra El Ouaamari, Veronica Popescu, Guy Laureys, Melissa Cambron, Miguel D'Haeseleer, Lander Willem, Judith Derdelinckx, Tatjana Reynders, Barbara Willekens   +11 more
wiley   +1 more source

Research progress in myocardial function and diseases related to muscarinic acetylcholine receptor (Review). [PDF]

Int J Mol Med
Shen C, Zuo Q, Shao Z, Lin Y, Chen S.
europepmc   +1 more source

Ten‐Year Outcomes of Anticholinergic Use Among Older Adults With Intellectual Disability: Findings From the Intellectual Disability Supplement to the Irish Longitudinal Study on Ageing (IDS‐TILDA)

Journal of Intellectual Disability Research, Volume 69, Issue 11, Page 1284-1294, November 2025.
ABSTRACT Background People with intellectual disability are frequently exposed to medication with anticholinergic activity. In the general population, the long‐term exposure to anticholinergics has been associated with declines in both physical and cognitive function.
Lamya Al Shuhaimi, Ian D. Maidment, Martin C. Henman, Phyo K. Myint, Juliette O'Connell, Caitríona Ryan, Philip McCallion, Mary McCarron, Maire O'Dwyer   +8 more
wiley   +1 more source

Correction to: From theory to therapy: unlocking the potential of muscarinic receptor activation in schizophrenia with the dual M1/M4 muscarinic receptor agonist xanomeline and trospium chloride and insights from clinical trials. [PDF]

Int J Neuropsychopharmacol
europepmc   +1 more source

Effect of N‐Butylscopolammonium Bromide and Metamizol Sodium on Heart Rate, Blood Pressure, and Echocardiographic Measurements in Warmblood Horses With Aortic and Mitral Valve Regurgitation

Journal of Veterinary Internal Medicine, Volume 39, Issue 6, November/December 2025.
ABSTRACT Background Administration of N‐butylscopolammonium bromide (NBB) with metamizol sodium (NBBM) causes tachycardia and hypertension, and has been associated with accentuated cardiac murmurs. Objectives To evaluate the effect of a pharmacological challenge using NBBM on valvular regurgitation and cardiac murmurs in horses with aortic (AR) and ...
Alexander Dufourni, Marie Demeyere, Ingrid Vernemmen, Glenn Van Steenkiste, Lize‐Maria Verhaeghe, Gunther van Loon, Annelies Decloedt   +6 more
wiley   +1 more source

Cholinergic system in schizophrenia: A systematic review and meta-analysis. [PDF]

Mol Psychiatry
Saint-Georges Z, MacDonald J, Al-Khalili R, Hamati R, Solmi M, Keshavan MS, Tuominen L, Guimond S.   +7 more
europepmc   +1 more source

Intramural Blood Vessels as a Primary Site of Vascular LUTS

LUTS: Lower Urinary Tract Symptoms, Volume 17, Issue 6, November 2025.
ABSTRACT Ischaemia has been considered a primary cause of lower urinary tract symptoms (LUTS). The existing concept is that ischaemic LUTS develops subsequent to structural narrowing of feeder arteries of the LUT due to atherosclerosis. However, the distribution of blood flow within each LUT organ that is regulated by intramural microvasculature should
Hikaru Hashitani, Retsu Mitsui
wiley   +1 more source

Bioorganic Chemistry, Toxinology, and Pharmaceutical Uses of <i>Datura</i> Metabolites and Derivatives. [PDF]

Toxins (Basel)
Thawabteh AM, Sulaiman S, Alabed IO, Scrano L, Karaman D, Karaman R, Bufo SA.   +6 more
europepmc   +1 more source

The Inhibitory Effects of Ferula assafoetida on Muscarinic Receptors of Guinea-Pig Tracheal Smooth Muscle

, 2015
Mohammad Reza Khazdair, Mohammad Hossein Boskabady, Majid Kiyanmehr, Milad Hashemzehi, Mehrdad Iranshahi   +4 more
openalex   +1 more source

Effect of STW 5‐II (Iberogast‐N) on Tolerance to Gastric Gas in Patients With Functional Dyspepsia. The IBO‐2 Study

Neurogastroenterology &Motility, Volume 37, Issue 11, November 2025.
In a parallel, placebo‐controlled study with direct gas infusion into the stomach, STW 5‐II reduced the perception of abdominal symptoms in patients with dyspepsia complaining of bloating when compared to placebo, with a minor effect on gas transit and evacuation, and no effect on visible abdominal distension.
Ariadna Aguilar, Luis Alcala‐Gonzalez, Claudia Barber, Javier Santos, Beatriz Lobo, Carolina Malagelada, Jordi Serra   +6 more
wiley   +1 more source